학술논문
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial
Document Type
Article
Author
Nitz, U.; Gluz, O.; Graeser, M.; Kuemmel, S.; zu Eulenburg, C.; Kates, R.; Wuerstlein, R.; Harbeck, N.; Christgen, M.; Kreipe, H.H.; Grischke, E.-M.; Braun, M.; Augustin, D.; Potenberg, J.; Krauss, K.; Schumacher, C.; Forstbauer, H.; Reimer, T.; Stefek, A.; Fischer, H.H.; Pelz, E.; von Schumann, R.; Kuhn, W.; Polata, S.; Bielecki, W.; Meyer, R.; Just, M.; Kraudelt, S.; Siggelkow, W.; Wortelmann, H.; Kleine-Tebbe, A.; Leitzen, L.; Kirchhof, H.; Krabisch, P.; Hackmann, J.; Depenbusch, R.; Gnauert, K.; Staib, P.; Lehnert, A.; Hoffmann, O.; Briest, S.; Lindner, C.; Heyl, V.; Bauer, L.; Uleer, C.; Mohrmann, S.; Viehstaedt, N.; Malter, W.; Link, T.; Buendgen, N.; Tio, J.
Source
In: The Lancet Oncology . (The Lancet Oncology, May 2022, 23(5):625-635)
Subject
Language
English
ISSN
14745488
14702045
14702045